Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes

被引：0
|
作者：
Te Li
Xu Wan
Jin Ma
Bin Wu
机构：
[1] Fuwai Yunnan Cardiovascular Hospital,Department of Pharmacy
[2] Affiliated with the Kunming Medical University,Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine
[3] Shanghai Jiaotong University,Department of Endocrinology, Ren Ji Hospital, School of Medicine
[4] Shanghai Jiaotong University,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Cost-effectiveness; Chinese setting; Diabetes; Statin treatment; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2214 / 2223
页数：9
相关论文
共 50 条
  • [31] Cost-effectiveness of atorvastatin 10 mg daily in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada
    Khoury, Hanane
    Wagner, Monika
    Merikle, Elizabeth
    Johnson, Scott J.
    Roberts, Craig
    CIRCULATION, 2008, 117 (21) : E450 - E450
  • [32] COST-EFFECTIVENESS OF ADDING A PHARMACIST TO THE PRIMARY CARE TEAM FOR THE MANAGEMENT OF TYPE 2 DIABETES PATIENTS
    Yu, J.
    Shah, B.
    Ip, E. J.
    Chan, J.
    VALUE IN HEALTH, 2012, 15 (04) : A181 - A181
  • [33] COST-EFFECTIVENESS OF NON-STATIN LIPID-MODIFYING AGENTS FOR PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW
    Abushanab, D.
    Al-Badriyeh, D.
    Marquina, C.
    Bailey, C.
    Jaam, M.
    Liew, D.
    Ademi, Z.
    VALUE IN HEALTH, 2022, 25 (01) : S98 - S98
  • [34] Cost-effectiveness analysis of a carbose in the prevention of type 2 diabetes in South Korea
    JongMann, K.
    Clegg, J. P.
    Chang, K.
    JuYeol, P.
    Wittrup-Jensen, K. U.
    Valentine, W. J.
    VALUE IN HEALTH, 2007, 10 (06) : A262 - A262
  • [35] The cost-effectiveness of screening for type 2 diabetes
    Engelgau, MM
    Narayan, KMV
    Thompson, TJ
    Boyle, JP
    Williamson, DF
    Manninen, DL
    Dong, FB
    Orians, CE
    Dasbach, EJ
    Teutsch, SM
    Eastman, R
    Herman, WH
    Songer, TJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (20): : 1757 - 1763
  • [36] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN PERU
    Elgart, J. F.
    Gonzalez, L.
    Prestes, M.
    Manrique, H.
    Solorzano, J.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2016, 19 (03) : A203 - A203
  • [37] Cost-effectiveness of primary prevention of CVD from the UKNHS perspective: A comparison of men and women with type 2 diabetes
    Davies, A
    Kingslake, S
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 104 - 105
  • [38] Cost-Effectiveness Of Drug Compliance In Type 2 Diabetes Mellitus Patients
    Maciel, Olga
    Vera, Zully
    Marin, Gustavo H.
    Morinigo, Macarena
    Maidana, Mabel
    Mastroianni, Patricia
    RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES, 2018, 9 (05): : 1824 - 1829
  • [39] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ARGENTINA
    Rodriguez, L.
    Lew, D.
    VALUE IN HEALTH, 2020, 23 : S115 - S115
  • [40] Cost-Effectiveness Analysis of the EndoBarrier Device in Patients with Type 2 Diabetes
    Sen Gupta, Piya
    Armstrong, Stephanie
    Amiel, Stephanie A.
    Ryder, Robert E.
    Pennington, Mark W.
    DIABETES, 2018, 67
12345